These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2666363)
41. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ; N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759 [TBL] [Abstract][Full Text] [Related]
42. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. Fowble B; Gray R; Gilchrist K; Goodman RL; Taylor S; Tormey DC J Clin Oncol; 1988 Jul; 6(7):1107-17. PubMed ID: 3292711 [TBL] [Abstract][Full Text] [Related]
43. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. Richards MA; O'Reilly SM; Howell A; George WD; Fentiman IS; Chaudary MA; Crowther D; Rubens RD J Clin Oncol; 1990 Dec; 8(12):2032-9. PubMed ID: 2230895 [TBL] [Abstract][Full Text] [Related]
44. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133 [TBL] [Abstract][Full Text] [Related]
45. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS; Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830 [TBL] [Abstract][Full Text] [Related]
46. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377 [TBL] [Abstract][Full Text] [Related]
47. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. Tannock IF; Boyd NF; DeBoer G; Erlichman C; Fine S; Larocque G; Mayers C; Perrault D; Sutherland H J Clin Oncol; 1988 Sep; 6(9):1377-87. PubMed ID: 2458438 [TBL] [Abstract][Full Text] [Related]
48. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. Bonadonna G; Valagussa P; Tancini G; Rossi A; Brambilla C; Zambetti M; Bignami P; Di Fronzo G; Silvestrini R NCI Monogr; 1986; (1):45-9. PubMed ID: 3534590 [TBL] [Abstract][Full Text] [Related]
49. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
50. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217 [TBL] [Abstract][Full Text] [Related]
51. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A; J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592 [TBL] [Abstract][Full Text] [Related]
52. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715 [TBL] [Abstract][Full Text] [Related]
53. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452 [TBL] [Abstract][Full Text] [Related]
54. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M; Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748 [TBL] [Abstract][Full Text] [Related]
55. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Geller NL; Hakes TB; Petroni GR; Currie V; Kaufman R Cancer; 1990 Oct; 66(8):1678-84. PubMed ID: 2208022 [TBL] [Abstract][Full Text] [Related]
56. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397 [TBL] [Abstract][Full Text] [Related]
57. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721 [TBL] [Abstract][Full Text] [Related]
58. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861 [TBL] [Abstract][Full Text] [Related]
59. [The adjuvant chemotherapy of breast cancer]. Semiglazov VF; Golubeva OM; Bavli IaL; Ivanova OA; Topuzov EE Vopr Onkol; 1992; 38(10):1187-94. PubMed ID: 1343144 [TBL] [Abstract][Full Text] [Related]
60. Adjuvant systemic therapy for resectable breast cancer. Bonadonna G; Valagussa P J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]